{
  "id": "CD015536.PUB2",
  "draft": "# Is entecavir (a type of antiviral medicine) effective and safe for children and adults with chronic hepatitis B (a long-term liver infection)?\n**Key Messages**\n- Due to a lack of robust evidence, the benefits and risks of entecavir (a type of antiviral medicine) for children and adults with chronic hepatitis B (a long-term liver infection) are unclear, including its effects on all-cause mortality (death from any cause) and serious adverse events (unwanted or harmful effects).\n- Entecavir may have some benefits, but the current evidence does not allow us to understand its effects fully, particularly because no studies reported on health-related quality of life (a person's overall well-being, including their physical, emotional, and social health).\n- Future research should focus on providing high-quality evidence about the benefits and harms of entecavir for people with chronic hepatitis B, including its long-term effects and potential impacts on health-related quality of life.\n**Introduction**\n### What is chronic hepatitis B and why is it a problem?\nChronic hepatitis B is a major worldwide public health concern. It is a liver infection caused by the hepatitis B virus that can lead to serious health problems, including liver damage, liver cancer, and even death. The virus is transmitted through bodily fluids, such as blood and semen, and can be spread through sexual contact, sharing needles, or from mother to child during birth. Common treatments for chronic hepatitis B include antiviral medications, such as entecavir, which can help slow the progression of the disease.\n### What did the review authors want to find out?\nThe review authors wanted to evaluate the benefits and harms of entecavir, a commonly used antiviral medication, compared to no treatment or placebo in children and adults with chronic hepatitis B. They aimed to determine the effect of entecavir on critical outcomes such as all-cause mortality, health-related quality of life, and the proportion of people with serious adverse events. The authors also wanted to assess the certainty of the evidence and identify any gaps in knowledge that need to be addressed.\n**Methods**\n### Search Strategy\nWe searched for studies comparing entecavir with no treatment or placebo in people with chronic hepatitis B.\n### Data Synthesis\nWe summarized the results of the identified studies.\n### Confidence Assessment\nWe rated our confidence in the evidence.\n**Results**\n### What did we find?\nWe found 22 studies that involved 2940 people with chronic hepatitis B. The studies were conducted over a period of 5 weeks to 228 weeks. One trial included participants between 14 years and 55 years of age, one trial included only children, 19 trials included only adults, and one trial did not provide the age of participants. The experimental intervention was oral entecavir, and the comparator in 12 trials was no treatment, and in 10 trials was placebo. Fourteen trials equally administered co-interventions to the trial participants in the entecavir and no treatment and placebo groups. This Cochrane review had no dedicated funding. Entecavir may reduce or have little to no effect on serious adverse events in people with chronic hepatitis B, but we are very uncertain about the results. It is unclear if entecavir has an effect on all-cause mortality or health-related quality of life.\n**Limitations**\nThe evidence is limited due to a high or unclear risk of bias in most trials, very small study sizes, few cases of the condition/event, and an insufficient number of studies to draw confident conclusions.\n**Currency**\nThe evidence is up to date to July 2024.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 629,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 26,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 24.192307692307693,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 13,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 42,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 23,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 22,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 22.0 to <13.0 (median)"
        },
        "nouns": {
          "value": 191,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 191.0 to <116.0 (median)"
        },
        "flesch_reading_ease": {
          "value": 48.45309863030454,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 12.511136724960256,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 12.411527455056863,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 10.123561208267088,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 17.371676654029596,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 54.2400024458848,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 7.269230769230769,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 14,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 14.0 to <12.1 (median)"
        },
        "dale_chall_readability": {
          "value": 7.551083135624312,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 253,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 253.0 to <160.0 (median)"
        },
        "complex_words": {
          "value": 121,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 121.0 to <84.0 (median)"
        },
        "long_words": {
          "value": 189,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 189.0 to <122.0 (median)"
        }
      },
      "word_count_status": {
        "word_count": 629,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 629 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 1,
        "P50_count": 6,
        "P75_count": 5,
        "P90_count": 6,
        "P10_count": 0,
        "BEYOND_P90_count": 0,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 5.555555555555555,
        "P50_percentage": 33.33333333333333,
        "P75_percentage": 27.77777777777778,
        "P90_percentage": 33.33333333333333,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 0,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 33.33333333333333,
        "overall_assessment": "MODERATE CONFORMITY WITH PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "The draft is not approved due to a critical formatting issue with subheadings and several clarity and style issues that impact readability for a patient audience. The 'Methods' section subheadings are not phrased as questions, which is a direct violation of the Master Style Guide. Additionally, the text contains several long, noun-heavy sentences with complex vocabulary, contributing to lower readability scores and making the content harder to digest. There is also room to improve the use of active voice for more direct communication.",
      "pls_evaluation_summary": "The PLS evaluation results show moderate conformity with typical PLS patterns. While some metrics like Coleman-Liau Index, active voice, pronouns, Flesch Reading Ease, and RIX are in the best quartile (P25/P75), a significant portion of features (33.3%) deviate from typical patterns, falling into the P90 range. Specifically, the draft exhibits higher than typical nominalization (22.0, P90), noun count (191.0, P90), and various measures of vocabulary complexity including SMOG Index (14.0, P90), Dale-Chall complex words (253.0, P90), complex words (121.0, P90), and long words (189.0, P90). The average words per sentence (24.19, P75) is also on the higher side. These deviations suggest that the text could benefit from simpler vocabulary, shorter sentences, and more direct phrasing to enhance readability for the target audience."
    }
  ]
}